Holen Sie sich die Stockscreener-App
1.33
3.10%
0.04
Schlusskurs vom Vortag:
$1.29
Offen:
$1.3
24-Stunden-Volumen:
1.04M
Relative Volume:
0.86
Marktkapitalisierung:
$160.76M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.5115
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+9.02%
1M Leistung:
+5.56%
6M Leistung:
+65.18%
1J Leistung:
-17.39%
1-Tages-Spanne:
$1.28
$1.34
1-Wochen-Bereich:
$1.18
$1.35
52-Wochen-Spanne:
$0.71
$1.89
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.33 | 155.92M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus BioSciences stock jumps after positive cancer drug survival data By Investing.com - Investing.com UK
Coherus BioSciences stock jumps after positive cancer drug survival data - Investing.com
LOQTORZI plus chemotherapy shows 31-month survival benefit in cancer study - Investing.com
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - The Manila Times
Coherus Announces Six-Year JUPITER-02 Follow-up Results - GlobeNewswire
Coherus Oncology (CHRS) price target decreased by 11.77% to 5.10 - MSN
Why Coherus Oncology Inc. (8C5) stock stays on top picksTrade Risk Summary & Daily Technical Forecast Reports - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Coherus Oncology, Inc. (NASDAQ:CHRS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Can Coherus Oncology Inc. (8C5) stock survive global slowdown2025 Earnings Surprises & Safe Swing Trade Setups - BỘ NỘI VỤ
Is Coherus Oncology Inc 8C5 a good long term investmentEconomic Impact on Stocks & Build Wealth Brick by Brick With Us - earlytimes.in
What analysts say about Coherus Oncology Inc 8C5 stockGap Up/Gap Down Analysis & Outstanding Profit Strategies - earlytimes.in
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Will Coherus Oncology Inc. (8C5) stock top growth indexesJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock outperform value peersPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can Coherus Oncology Inc. (8C5) stock attract analyst upgradesJuly 2025 Selloffs & Risk Managed Investment Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billOil Prices & Technical Confirmation Trade Alerts - newser.com
How Coherus Oncology Inc. (8C5) stock reacts to Fed tighteningWeekly Trade Analysis & Consistent Growth Stock Picks - newser.com
Is Coherus Oncology Inc. (8C5) stock included in top ETFs2025 Top Decliners & AI Forecasted Entry and Exit Points - newser.com
Can Coherus Oncology Inc. (8C5) stock retain market dominanceWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):